- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06055959
Eine Studie zur Bewertung von subkutanem Zilucoplan bei pädiatrischen Teilnehmern mit generalisierter Myasthenia gravis (ziMyG)
Eine multizentrische offene, unkontrollierte Studie zur Bewertung der Pharmakokinetik, Pharmakodynamik, Sicherheit, Verträglichkeit und Aktivität von Zilucoplan bei pädiatrischen Studienteilnehmern im Alter von 2 bis unter 18 Jahren mit Acetylcholinrezeptor-Antikörper-positiver generalisierter Myasthenia gravis
The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, safety, tolerability, immunogenicity and activity of zilucoplan (ZLP) in pediatric study participants with generalized myasthenia gravis (gMG).
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 2
- Phase 3
Kontakte und Standorte
Studienkontakt
- Name: UCB Cares
- Telefonnummer: 001 844 599 2273
Studieren Sie die Kontaktsicherung
- Name: UCB Cares
- Telefonnummer: +18445992273 (USA)
- E-Mail: ucbcares@ucb.com
Studienorte
-
-
-
Milan, Italien
- Rekrutierung
- Mg0014 40144
-
-
-
-
-
Katowice, Polen
- Rekrutierung
- Mg0014 40774
-
Warsaw, Polen
- Aktiv, nicht rekrutierend
- Mg0014 40218
-
-
-
-
-
Seoul, Südkorea
- Rekrutierung
- Mg0014 20220
-
Seoul, Südkorea
- Zurückgezogen
- Mg0014 20104
-
-
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60611
- Zurückgezogen
- Mg0014 50168
-
-
Texas
-
Denton, Texas, Vereinigte Staaten, 76208
- Zurückgezogen
- Mg0014 50574
-
-
-
-
-
Glasgow, Vereinigtes Königreich
- Rekrutierung
- Mg0014 40735
-
London, Vereinigtes Königreich
- Rekrutierung
- Mg0014 40736
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
United States of America (USA) specific inclusion criterion:
- Participant must be 12 to <18 years of age at the time of signing the Informed consent/assent according to local regulation
Rest of world (ROW) specific inclusion criterion:
- Participant must be 2 to <18 years of age at the time of signing the Informed consent/assent according to local regulation
Global inclusion criteria:
- Participant has a diagnosis of generalized myasthenia gravis (gMG) confirmed by a prior positive serologic test result to acetylcholine receptor (AChR) prior to Screening
- Participant meets the criteria as defined by the Myasthenia Gravis Foundation of America (MGFA) Clinical Classification II to IV at Screening
- Participants with gMG, including:
- An MG-activities of daily living (MG-ADL) total score of 6 or more in adolescents from 12 years to <18 years of age at Screening
- Documented weakness in at least 1 limb, neck, or bulbar muscle in children from 2 years to <12 years of age at Screening (does not apply to US)
- Documented vaccination against meningococcal infections within 3 years prior to study start. If not fully vaccinated, participants must receive appropriate prophylactic antibiotic treatment until at least 2 weeks after the initial dose of vaccine(s)
Exclusion Criteria:
- Participant has known positive serology for muscle-specific kinase
- Participant has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the participant's ability to participate in this study
- Participant has had a thymectomy within 6 months prior to Baseline
- Participant has minimal Manifestation Status of MG based on the clinical judgement of the Investigator
- Current or recent systemic infection within 2 weeks prior to Baseline or infection requiring intravenous antibiotics within 4 weeks prior to Baseline
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Zilucoplan Arm
Study participants will receive zilucoplan in pre-defined dose based on their weight. |
Zilucoplan will be administered subcutaneously to pediatric study participants.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Plasma concentrations of zilucoplan (ZLP) sampled at Week 4 (Day 29)
Zeitfenster: Week 4 (Day 29)
|
Blood samples will be collected for measurement of plasma concentrations of ZLP on Day 29 predose. |
Week 4 (Day 29)
|
|
Change from Baseline in sheep red blood cell (sRBC) lysis at Week 4 (Day 29)
Zeitfenster: Week 4 (Day 29)
|
Samples for measurement of sRBC lysis will be collected on Day 29 predose. |
Week 4 (Day 29)
|
|
Change from Baseline in complement component 5 (C5) levels at Week 4 (Day 29)
Zeitfenster: Week 4 (Day 29)
|
Samples for measurement of C5 will be collected on Day 29 predose. |
Week 4 (Day 29)
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Occurence of treatment-emergent adverse events (TEAEs) during the course of the study
Zeitfenster: From Baseline (Day 1) to Safety-Follow-Up Visit (up to Week 15)
|
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. |
From Baseline (Day 1) to Safety-Follow-Up Visit (up to Week 15)
|
|
Occurrence of treatment-emergent serious adverse events (TESAEs)
Zeitfenster: From Baseline (Day 1) to Safety-Follow-Up Visit (up to Week 15)
|
A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: Results in death Is life-threatening Requires inpatient hospitalization or prolongation of existing hospitalization Results in persistent disability/incapacity Is a congenital anomaly/birth defect Important medical events |
From Baseline (Day 1) to Safety-Follow-Up Visit (up to Week 15)
|
|
Occurrence of TEAEs leading to permanent withdrawal of investigational medicinal product (IMP)
Zeitfenster: From Baseline (Day 1) to Safety-Follow-Up Visit (up to Week 15)
|
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. AEs leading to permanent withdrawal of study medication. |
From Baseline (Day 1) to Safety-Follow-Up Visit (up to Week 15)
|
|
Occurrence of treatment-emergent infections
Zeitfenster: From Baseline (Day 1) to Safety-Follow-Up Visit (up to Week 15)
|
Percentage of participants who experienced treatment-emergent infections as adverse events. An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. |
From Baseline (Day 1) to Safety-Follow-Up Visit (up to Week 15)
|
|
Occurrence of antidrug antibody (ADA) and anti- polyethylene glycol (PEG) antibodies at Week 4 (Day 29)
Zeitfenster: Week 4 (Day 29)
|
ADA and anti-PEG antibodies will be evaluated in serum samples. |
Week 4 (Day 29)
|
|
Change in MG-activities of daily living (MG-ADL) score from Baseline to Week 4 (Day 29).
Zeitfenster: Week 4 (Day 29)
|
The MG-ADL score is an 8-item patient-reported outcome (PRO) instrument. The MG-ADL targets symptoms and disability across ocular, bulbar, respiratory, and axial symptoms. The item responses are scored from 0 to 3, and the total score of MG-ADL is the sum of the 8 items and ranges from 0 to 24, with a higher score indicating more disability. |
Week 4 (Day 29)
|
|
Change in Quantitative MG (QMG) score from Baseline to Week 4 (Day 29)
Zeitfenster: Week 4 (Day 29)
|
QMG score is a standardized and validated quantitative strength scoring system that was developed specifically for MG. The QMG total score is obtained by summing the responses to each individual item (13 items; Responses: None=0, Mild=1, Moderate=2, Severe=3). The score ranges from 0 to 39, with lower scores indicating lower disease activity. |
Week 4 (Day 29)
|
|
Myasthenia Gravis Foundation of America Post-Interventional Status (MGFA-PIS) at Week 4 (Day 29)
Zeitfenster: Week 4 (Day 29)
|
The MGFA-PIS is a physician-determined assessment of clinical symptoms of MG after initiation of MG specific therapy. For the purpose of the current study, Minimal Manifestation will be determined at each scheduled time point after treatment initiation (rather than after 1 year). Change in status (improved, unchanged, worse, exacerbation, or died of MG) will also be determined. |
Week 4 (Day 29)
|
|
Change in Pediatric Quality of Life Inventory (PedsQoL), Version 4 domain scores from Baseline to Week 4 (Day 29)
Zeitfenster: Week 4 (Day 29)
|
The PedsQoL generic core scale (Version 4) is a validated instrument that is suitable for use with pediatric populations. PedsQoL generic core scales assess Physical Functioning, Emotional Functioning, Social Functioning, and School Functioning. The scale has 23 items with a score range of 0 to 4. Following transformation, the score range of each domain as well as the total score is 0-100 with higher scores indicating higher HRQoL. |
Week 4 (Day 29)
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: UCB Cares, 001 844 599 2273
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Nervensystems
- Neubildungen nach Standort
- Neubildungen
- Neuromuskuläre Erkrankungen
- Autoimmunerkrankungen
- Erkrankungen des Immunsystems
- Autoimmunerkrankungen des Nervensystems
- Neurodegenerative Krankheiten
- Paraneoplastische Syndrome, Nervensystem
- Neubildungen des Nervensystems
- Paraneoplastische Syndrome
- Erkrankungen der neuromuskulären Verbindungen
- Myasthenia gravis
- Zilucoplan
Andere Studien-ID-Nummern
- MG0014
- U1111-1290-3349 (Andere Kennung: World Health Organization (WHO))
- 2022-502072-23 (Registrierungskennung: EU Clinical Trials)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
IPD-Sharing-Zeitrahmen
Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
IPD-Sharing-Zugriffskriterien
Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
- CSR
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .